European Hemostats Market: By Type; By Treatment; By End Users & By Region - Forecast 2015-2022

  • ID: 4425358
  • Report
  • Region: Europe
  • 167 pages
  • IndustryARC
1 of 3
Hemostats are instruments used to reduce or halt bleeding during surgery. These can be enabled by the time privileged approaches of smearing pressure, stitching the bleeding or using thermal energy devices. Bleeding control is a significant factor in surgical and trauma settings as it reduces the risk of infection, save operative time and reduces the patient stay in hospitals. As surgical procedures evolve to be more refined and non-invasive, the use of fast acting biologically and synthetically derived hemostats, encompassing fibrin sealants, flow able gelatins and adhesives is becoming increasingly prevalent. Some of the consideration parameters for choosing a particular hemostatic agent include efficiency, type of surgery, patient condition and active bleeding tissue versus pooled blood sites and cost.

European hemostats market is comprehended by type, treatment and end users. Based on type the market is categorized into thrombin based hemostats, gelatin based hemostats, collagen based hemostats, oxidized regenerated cellulose based hemostats, combination hemostats and others. By treatment the market is further segmented into cardiac surgery, vascular procedures, soft tissue reconstructions, spinal procedures, hepatic resection and others. Based on end users the market is categorized into hospitals, surgery centers, nursing homes and others.

European hemostats market is further analyzed on the basis of countries such as: U.K., Ireland, France, Germany, Spain, Italy, Netherlands, Belgium, Austria, Norway, Sweden, Finland, Denmark, Switzerland, Portugal, Rest of Europe.

Sample companies profiled in this report are:
B Braun Melsungen AG (Germany),
Gelita Medical GmbH (Germany),
Equimedical (Netherlands),
Pfizer Inc. (U.S.),
Johnson & Johnson Services, Inc. (U.S.),

Increase in number of surgical procedures will propel the growth of the market. Wide range of applications, continuous advancement in product portfolio, technological advancement facilitating the end users and insurance support to manufacturers in promoting tissue sealants are the major driving forces of European hemostats market.

The research methodology opted for this report incorporates initial segregation of the market by type, treatment, end users and countries. This was followed by mining of market volume and revenue of different type of hemostats employed by various end users with respect to countries are considered. Bottom up approach was then followed for estimating the global market size and its forecast for period 2017 to 2023. The data figures and supporting insights so collated were validated through primary research process by Key Opinion Leaders (KOLs) which comprised of manufacturers, distributors, suppliers, associations and end users.
Note: Product cover images may vary from those shown
2 of 3
1. European Hemostats Market Overview

2. European Hemostats Executive Summary

3. European Hemostats Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
3.2.4. Patent Analysis

4. European Hemostats Market Forces
4.1. Market Drivers
4.2. Market Constraints & Challenges
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threats from New Entrants
4.3.4. Threat from Substitutes
4.3.5. Degree of Competition

5. European Hemostats Market-Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunity Analysis
5.4. Product/Market Life cycle Analysis

6. European Hemostats Market -By Type
6.1. Introduction
6.2. Thrombin Based Hemostats
6.3. Gelatin Based Hemostats
6.4. Collagen Based Hemostats
6.5. Oxidized Regenerated Cellulose Based Hemostats
6.6. Combination Hemostats
6.7. Others

7. European Hemostats Market -By Treatment
7.1. Introduction
7.2. Cardiac Surgery
7.3. Vascular Procedures
7.4. Soft Tissue Reconstructions
7.5. Spinal Procedures
7.6. Hepatic Resection
7.7. Others

8. European Hemostats Market-By End Users
8.1. Introduction
8.2. Hospitals
8.3. Surgery Centres
8.4. Nursing Homes
8.5. Others

9. European Hemostats Market -By Country
9.1. Introduction
9.2. U.K.
9.3. Ireland
9.4. France
9.5. Germany
9.6. Spain
9.7. Italy
9.8. Netherlands
9.9. Belgium
9.10. Austria
9.11. Norway
9.12. Sweden
9.13. Finland
9.14. Sweden
9.15. Denmark
9.16. Switzerland
9.17. Portugal
9.18. Rest of Europe

10. European Hemostats Market Entropy
10.1. Expansion
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract

11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
11.1. Baxter AG
11.2. B Braun Melsungen AG (Germany)
11.3. Gelita Medical GmbH (Germany)
11.4. Equimedical (Netherlands)
11.5. Pfizer Inc. (U.S.)
11.6. Johnson & Johnson Services, Inc. (U.S.)
11.7. Thrombotargets Corporation (Spain)
11.8. RESORBA Medical GmbH (Germany)
11.9. C R BARD Inc.
11.10. Mallinckrodt Pharmaceuticals
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"

12. Appendix
12.1. List of Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Expert Insights
12.5. Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown